<b>Conclusions:</b> FAM64A drives BLCA progression via PI3K/mTORC2/AKT-mediated EMT, serving as a potential prognostic biomarker and therapeutic target for metastatic BLCA. Here, PIMREG is linked to bladder transitional cell carcinoma.